NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces it has commenced an investigation of Cellectis S.A. (“Cellectis” or the “Company”) (NASDAQ: CLLS) concerning possible violations of federal securities laws.
On September 5, 2017, Cellectis revealed that the U.S. Food and Drug Administration had suspended two of Cellectis’ early-stage studies for its experimental blood cancer treatment UCART123, following the death of a patient. Following this news, Cellectis stock has dropped as much as $10.18 per share, or 31.63%, during intraday trading on September 5, 2017. To obtain additional information, go to:
or contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.